Gilead and Lyndra to collab on long acting oral HIV drugs

US-based Lyndra Therapeutics has signed an agreement with Gilead Sciences to develop and commercialise ultra-long acting oral therapies to treat HIV. Gilead will have exclusive rights to leverage Lyndra’s proprietary long-acting drug development platform for HIV therapies. Lyndra was founded in 2015 with the aim of improving medication adherence by focusing on developing longer acting

Continue Reading